National Jewish Health is a Denver, Colorado academic hospital/clinic doing research and treatment in respiratory, cardiac, immune and related disorders. It is an internationally respected medical center that draws people from many countries to receive care.

There are 46 beds in National Jewish Health.

During the past decade, National Jewish Health conducted 201 clinical trials. In the 10-year time frame, 201 clinical trials started and 115 clinical trials were completed, i.e. on average, 57.2% percent of trials that started reached the finish line to date. In the past 5 years, 91 clinical trials started and 59 clinical trials were completed. i.e. 64.8% of trials that started reached the finish line.

Out of the total clinical trials conducted in "National Jewish Health" #1 sponsor was "National Jewish Health" with 88 trials, followed by "National Institute of Allergy and Infectious Diseases (NIAID)" with 26 trials sponsored, "Milton S. Hershey Medical Center" with 17 trials sponsored, "Vertex Pharmaceuticals Incorporated" with 15 trials sponsored and "Gilead Sciences" with 15 trials sponsored. Other sponsors include 221 different institutions and companies that sponsored additional 134 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "National Jewish Health" #1 collaborator was "National Heart, Lung, and Blood Institute (NHLBI)" with 56 trials as a collaborator, "Cystic Fibrosis Foundation" with 30 trials as a collaborator, "National Jewish Health" with 13 trials as a collaborator, "National Institutes of Health (NIH)" with 9 trials as a collaborator and "University of Alabama at Birmingham" with 7 trials as a collaborator. Other collaborators include 273 different institutions and companies that were collaborators in the rest 179 trials.

According to Clinical.Site data, the most researched conditions in "National Jewish Health" are "Cystic Fibrosis" (67 trials), "Asthma" (66 trials), "Idiopathic Pulmonary Fibrosis" (24 trials), "Atopic Dermatitis" (22 trials) and "Pulmonary Disease, Chronic Obstructive" (12 trials). Many other conditions were trialed in "National Jewish Health" in a lesser frequency.

Most popular intervention types in "National Jewish Health" are "Drug" (217 trials), "Other" (41 trials), "Biological" (34 trials), "Behavioral" (21 trials) and "Device" (18 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (92 trials), "IVA" (10 trials), "placebo" (7 trials), "AR101" (4 trials) and "ELX/TEZ/IVA" (4 trials). Other intervention names were less common.

The vast majority of trials in "National Jewish Health" are 375 trials for "All" genders and 6 trials for "Female" genders.

Currently, there are 75 active trials in "National Jewish Health". 1 are not yet recruiting, 45 are recruiting, 23 are Active, not recruiting, and 6 are Enrolling by invitation. In total, there were 238 completed trials in National Jewish Health, 3 suspended trials, and 41 terminated clinical trials to date.

Out of the total trials that were conducted in National Jewish Health, 32 "Phase 1" clinical trials were conducted, 108 "Phase 2" clinical trials and 98 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 25 trials, and there were also 42 trials that are defined as “Not Applicable".

National Jewish Health has several departments that took part in Clinical trials: "National Jewish Health-Western Hematology Oncology" - 95 trials, "National Jewish Health-Northern Hematology Oncology" - 77 trials, "National Jewish Health: Division of Pediatric Allergy and Clinical Immunology" - 4 trials, "National Jewish Health Interstitial Lung Disease Program" - 2 trials